Point mutation antibody development

Since the end of 2020, the characteristic of the SARS-CoV-2 virus, responsible for COVID-19, has been the emergence of a series of mutations. These mutations can impact virus features, including transmissibility and immunogenicity, thereby affecting the effectiveness of diagnostics, treatments, and vaccines. This situation is not limited to the virus alone, within biological organisms, continuous gene/amino acid mutations occur, often closely associated with the occurrence of diseases/tumors.


In the study of such biological issues, it is inevitable to develop antibodies that can recognize differentiated wild-type and mutant forms. Rabbit-derived antibodies, with their high sensitivity and smaller recognition epitopes, make the detection of single-point mutations more effective. Leveraging our proprietary rabbit single B cell antibody development platform,  We offer a one-stop development service for antibodies that can recognize point mutations.

Platform features
pAb&mAb
pAb&mAb

The development route is not conflicting, and rabbit polyclonal antibody and rabbit monoclonal antibody can be obtained respectively

Efficient
Efficient

Providing a large number of screening validation clones at once, rabbit antibodies have high sensitivity and smaller recognition epitopes

Information
Information

By PCR cloning sequencing, the original information of antibody heavy and light chains are avoided

Compatible
Compatible

Whether expressed in transient or stable cells, batches of stable recombinant antibodies are obtained without interference from animal sources

Data
Data

SDS/PAGE, Elisa analysis quality control Nanodrop quantitative

Service Content

Cycle

Project design
Project design

Preliminary investigation, communication and confirmation

1 day
Antigen preparation
Antigen preparation

Determine the production volume according to the demand

3-4 weeks
Immunization and single B cell screening
Immunization and single B cell screening

Four immunizations, screening positive B cell to culture

7-9 weeks
Recombinant expression and identification
Recombinant expression and identification

Antibody gene sequence amplification, recombinant expression, verification

12-14 weeks
Delivery
Delivery

Experimental report, antigen, antibody cloning vector, recombinant protein antigen, recombinant antibody

1 day
Case Show
Target protein A

Target A is a functional active enzyme protein, and amino acid mutation at a certain site leads to the difference in enzyme activity.

The mutant fragment was selected to prepare multiple anti-conjugated KLH as antigen and immunize rabbit monoclonal antibody development.

Target protein A
Please feel free to contact us for more information or a detailed quote！